Thromb Haemost 2009; 101(04): 789-791
DOI: 10.1160/TH08-02-0082
Letters to the Editor
Schattauer GmbH

Anti-β2-glycoprotein I ELISA assay: The influence of different antigen preparations

Anna Cavazzana
1   Rheumatology Unit, University of Padua, Italy
,
Vittorio Pengo
2   Cardiology Unit, University of Padua, Italy
,
Marta Tonello
1   Rheumatology Unit, University of Padua, Italy
,
Franco Noventa
3   5th Internal Medicine Unit, University of Padua, Italy
,
Claudia Grossi
4   IRCCS Auxologico Institute, University of Milan, Italy
,
Maria Orietta Borghi
4   IRCCS Auxologico Institute, University of Milan, Italy
,
Philippe de Moerloose
5   Angiology and Haemostasis Division, University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Guido Reber
5   Angiology and Haemostasis Division, University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Amelia Ruffatti
1   Rheumatology Unit, University of Padua, Italy
› Author Affiliations
Further Information

Publication History

Received: 12 February 2008

Accepted after major revision: 05 January 2009

Publication Date:
23 November 2017 (online)

 

 
  • References

  • 1 Miyakis S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
  • 2 Reber G. et al European Forum on Antiphospholipid Antibodies Standardization Group.. Variability of anti-β2-glycoprotein I antibody measurement by commercial assays. Thromb Haemost 2005; 94: 665-672.
  • 3 Tsutsumi A. et al. Heterogeneous behaviour of anti-β2-glycoprotein I antibodies on various commercial available enzyme immunoassay plates coated with β2-glycoprotein I. J Rheumatol 2000; 27: 391-396.
  • 4 Reber G. et al Standardization group of the European Forum on Antiphospholipid Antibodies.. Proposal for the measurement of anti-beta2-glycoprotein I Antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2: 1860-1862.
  • 5 Ichikawa K. et al. Beta 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-1461.
  • 6 Reber G. et al. Inter-laboratory variability of anti-β2-glycoprotein I measurements. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
  • 7 Cavazzana A. et al. An analysis of experimental conditions influencing the anti-β2-glycoprotein I ELISA assay results. Ann NY Acad Sci 2007; 1109: 484-492.
  • 8 Sanmarco M. et al. Heterogeneity of anti-beta2-glycoprotein I antibodies. A factor of variability in test results. Thromb Haemost 2005; 93: 80-87. (Erratum in: Thromb Haemost 2005; 93: 796–797.)
  • 9 Tincani A. et al. Minimal requirements for anti-phospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-558.
  • 10 Brandt JT. et al. Criteria for diagnosis of lupus anticoagulant: an update. On behalf of subcommittee on Lupus Anticoagulant/Antiphosphoipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
  • 11 Pengo V. et al. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
  • 12 Galli M. et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.
  • 13 Ichikawa K. et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461-2470.